Coya Therapeutics Inc
:COYA
Products, Regulatory
Coya Therapeutics, Inc. Announces Preclinical Data Supporting The Role Of Expanded Regulatory T Cells (Tregs) As Potential Disease-Modifying Treatment In An Animal Model Of Alzheimer’S Disease (
Published: 01/26/2023 14:14 GMT
Coya Therapeutics Inc (COYA) - Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (tregs) As Potential Disease-modifying Treatment in an Animal Model of Alzheimer’s Disease (ad).
Coya Therapeutics Inc- Initiation of Phase I Clinical Trials for Treg Enhancing Biologics in Neurodegenerative Diseases Expected in 2023.
Coya Therapeutics- Data Provide Preclinical Support for Treg Enhancing Therapies As Potential Treatment Strategy in Ad, Other Neurodegenerative Diseases.
Coya Therapeutics Inc- Initiation of Phase I Clinical Trials for Treg Enhancing Biologics in Neurodegenerative Diseases Expected in 2023.
Coya Therapeutics- Data Provide Preclinical Support for Treg Enhancing Therapies As Potential Treatment Strategy in Ad, Other Neurodegenerative Diseases.